Soligenix
Nasdaq SNGX · Princeton, NJ
Works in Cardiovascular · Dermatology · Genetic & rare · Hematology · Immunology · Oncology · Ophthalmology
Soligenix is a clinical trial sponsor based in Princeton, NJ, listed as Nasdaq SNGX. It has no active clinical trials as lead sponsor; its trials since 2021 were across 7 therapeutic areas. Since 2021 it has completed 6 trials and stopped 1 early.
Trial track record · since 2021
Financials · Nasdaq SNGX
Fundraising
Pipeline · 0 active trials
No active trials with this company as lead sponsor.
Questions about Soligenix
Soligenix has no active clinical trials as lead sponsor on ClinicalTrials.gov. Since 2021 it has completed 6 trials and stopped 1 early.
Soligenix is based in Princeton, NJ and is listed as Nasdaq SNGX. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Soligenix; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-08-26.
Approve Suite is not affiliated with Soligenix. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.